Search
for
Sort by
Research 61–90 of 389
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- The Possible Role of Antibodies in Alopecia: A Narrative Review
- Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Angelica sinensis promotes cortical regeneration of the thymus in mice with acute thymic involution induced by short-term rapamycin treatment
- Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
- Case Report: Alopecia areata in an adolescent after COVID-19 infection